Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists
Omer S. Ashruf, Jasmin Hundal, Ali Mushtaq, David C. Kaelber, Faiz Anwer, Abhay Singh
Abstract
This cohort study compares the risks of developing different hematologic cancers in patients with type 2 diabetes treated with glucagon-like peptide–1 receptor agonists (GLP-1RAs) compared with metformin and insulin.
Topics & Concepts
Glucagon-like peptide 1 receptorMedicineMetforminType 2 diabetesInternal medicineGlucagon-like peptide-1ReceptorCohortInsulinDiabetes mellitusEndocrinologyOncologyAgonistMetabolism, Diabetes, and CancerDiabetes Treatment and ManagementNeuroendocrine Tumor Research Advances